New treatments of bipolar disorder

Curr Psychiatry Rep. 1999 Dec;1(2):111-3. doi: 10.1007/s11920-999-0019-8.

Abstract

This clinical trials review is derived from the presentations made at the Third International Conference on Bipolar Disorder, held June 17-19, 1999 in Pittsburgh, PA, published as abstracts in Bipolar Disorders: An International Journal of Psychiatry and Neurosciences, Edited by Jair C. Soares, and Samuel Gershon. In this review, abstracts reporting on the efficacy of "third generation" anti-epileptic agents, including topiramate, lamotrigine, diphenylhydantoin, gabapentin, and the new generation antipsychotic agent, olanzapine in treating bipolar disorders are reviewed.

Publication types

  • Review

MeSH terms

  • Acetates / pharmacology
  • Acetates / therapeutic use
  • Amines*
  • Anticonvulsants / pharmacology
  • Anticonvulsants / therapeutic use
  • Antimanic Agents / pharmacology
  • Antimanic Agents / therapeutic use
  • Benzodiazepines
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / psychology
  • Clinical Trials as Topic
  • Cyclohexanecarboxylic Acids*
  • Fructose / analogs & derivatives
  • Fructose / pharmacology
  • Fructose / therapeutic use
  • Gabapentin
  • Humans
  • Lamotrigine
  • Olanzapine
  • Phenytoin / pharmacology
  • Phenytoin / therapeutic use
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / pharmacology
  • Pirenzepine / therapeutic use
  • Topiramate
  • Treatment Outcome
  • Triazines / pharmacology
  • Triazines / therapeutic use
  • gamma-Aminobutyric Acid*

Substances

  • Acetates
  • Amines
  • Anticonvulsants
  • Antimanic Agents
  • Cyclohexanecarboxylic Acids
  • Triazines
  • Topiramate
  • Benzodiazepines
  • Fructose
  • Pirenzepine
  • gamma-Aminobutyric Acid
  • Phenytoin
  • Gabapentin
  • Olanzapine
  • Lamotrigine